| 摘要 |
<p>The invention concerns a composition comprising marked befloxatone for use as medical imaging agent. The invention also concerns the use of marked befloxatone for producing a medical imaging agent for diagnosis in humans of pathological conditions related or not to modification of MAO-A distribution, and more particularly to neurological and/or psychiatric disorders; to chronic neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and the like); to neuronal and/or glial loss related to acute neurodegenerative diseases (cranial trauma, cerebral ischemia and the like); to psychiatric diseases (depression, schizophrenia); or to tobacco consumption. The invention further concerns a non-invasive method for determining tissue distribution of monoamine oxidase A of the human body.</p> |
